(Q84817240)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

title

The potential cost-effectiveness of infant pneumococcal vaccines in Australia (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

0 references

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

5

C Raina MacIntyre

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

author name string

Prudence Creighton

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

David J Philp

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

James G Wood

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

publication date

22 August 2011

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

volume

29

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

issue

45

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

page(s)

8077-8085

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

The current burden of pneumococcal disease in England and Wales

11 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Effect of pneumococcal conjugate vaccine on pneumococcal meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination--a review (2002-2006).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Huge impact of assumptions on indirect effects on the cost-effectiveness of routine infant vaccination with 7-valent conjugate vaccine (Prevnar).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Burden of invasive pneumococcal disease and serotype distribution among Streptococcus pneumoniae isolates in young children in Europe: impact of the 7-valent pneumococcal conjugate vaccine and considerations for future conjugate vaccines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Reduction in hospitalizations for pneumonia associated with the introduction of a pneumococcal conjugate vaccination schedule without a booster dose in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Cost of treating otitis media in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Effectiveness of seven-valent pneumococcal conjugate vaccine against invasive pneumococcal disease: a matched case-control study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typable Haemophilus influenzae: a randomised double-blind efficacy study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Pneumococcal conjugate vaccines for preventing otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Impact of the pneumococcal conjugate vaccine on otitis media

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Current face of acute otitis media: microbiology and prevalence resulting from widespread use of heptavalent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Timeliness of childhood immunisation in Australia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Effectiveness of heptavalent pneumococcal conjugate vaccine in children younger than five years of age for prevention of pneumonia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

The cost-effectiveness of pneumococcal conjugate vaccination in Australia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

The EQ-5D and the Health Utilities Index for permanent sequelae after meningitis: a head-to-head comparison.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Meningitis in infancy in England and Wales: follow up at age 5 years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

A population based study of the impact of corticosteroid therapy and delayed diagnosis on the outcome of childhood pneumococcal meningitis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

How to compare the efficacy of conjugate vaccines to prevent acute otitis media?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

A cost-utility analysis of second-line antibiotics in the treatment of acute otitis media in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

Changing epidemiology of invasive pneumococcal disease in Australian children after introduction of a 7-valent pneumococcal conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2011.08.050

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2011.08.050

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21864617%20AND%20SRC:MED&resulttype=core&format=json

11 February 2020

1 reference